SI2046292T1 - Formulacije za benzimidazolil piridil etre - Google Patents

Formulacije za benzimidazolil piridil etre

Info

Publication number
SI2046292T1
SI2046292T1 SI200730219T SI200730219T SI2046292T1 SI 2046292 T1 SI2046292 T1 SI 2046292T1 SI 200730219 T SI200730219 T SI 200730219T SI 200730219 T SI200730219 T SI 200730219T SI 2046292 T1 SI2046292 T1 SI 2046292T1
Authority
SI
Slovenia
Prior art keywords
formulations
pyridyl ethers
benzimidazolyl pyridyl
compound
mixture
Prior art date
Application number
SI200730219T
Other languages
English (en)
Inventor
Ahmad Hashash
Sean Ritchie
Kangwen Lin
Peng Shen
Augustus Okhamafe
Rampurna Gullapalli
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of SI2046292T1 publication Critical patent/SI2046292T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
SI200730219T 2006-07-21 2007-07-20 Formulacije za benzimidazolil piridil etre SI2046292T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US83271506P 2006-07-21 2006-07-21
EP07810647A EP2046292B1 (en) 2006-07-21 2007-07-20 Formulations for benzimidazolyl pyridyl ethers
PCT/US2007/016469 WO2008011154A2 (en) 2006-07-21 2007-07-20 Formulations for benzimidazolyl pyridyl ethers

Publications (1)

Publication Number Publication Date
SI2046292T1 true SI2046292T1 (sl) 2010-06-30

Family

ID=38819293

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200730219T SI2046292T1 (sl) 2006-07-21 2007-07-20 Formulacije za benzimidazolil piridil etre

Country Status (20)

Country Link
US (1) US8455662B2 (sl)
EP (1) EP2046292B1 (sl)
JP (1) JP2009544617A (sl)
KR (1) KR20090033904A (sl)
CN (1) CN101516335B (sl)
AT (1) ATE459338T1 (sl)
AU (1) AU2007275634B2 (sl)
BR (1) BRPI0715423A2 (sl)
CA (1) CA2657346A1 (sl)
CY (1) CY1110037T1 (sl)
DE (1) DE602007005139D1 (sl)
DK (1) DK2046292T3 (sl)
ES (1) ES2340631T3 (sl)
HR (1) HRP20100293T1 (sl)
MX (1) MX2009000770A (sl)
PL (1) PL2046292T3 (sl)
PT (1) PT2046292E (sl)
RU (2) RU2452469C2 (sl)
SI (1) SI2046292T1 (sl)
WO (1) WO2008011154A2 (sl)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20070427A1 (es) * 2005-08-30 2007-04-21 Novartis Ag Compuestos derivados de benzimidazoles sustituidos como inhibidores de tirosina quinasas
PE20130814A1 (es) * 2006-08-30 2013-08-08 Novartis Ag Sales de benzimidazolil piridil eteres y formulaciones que las contienen
AU2008251764B2 (en) * 2007-03-02 2012-09-13 Novartis Ag Solid forms of a Raf kinase inhibitor
WO2010040055A2 (en) * 2008-10-03 2010-04-08 Intekrin Therapeutics, Inc. Oral pharmaceutical formulations for antidiabetic compounds
JO3434B1 (ar) * 2009-07-31 2019-10-20 Millennium Pharm Inc مركبات صيدلانية لمعالجة السرطان وامراض واضطرابات اخري
JP5936609B2 (ja) * 2010-06-29 2016-06-22 ベラステム インコーポレイテッド キナーゼインヒビターの経口製剤
JP5923499B2 (ja) 2010-06-30 2016-05-24 ベラステム インコーポレイテッド キナーゼインヒビターの合成および使用
CN102336740B (zh) * 2010-07-27 2013-07-24 中国科学院上海药物研究所 一类咪唑类化合物及其用途
CN103301067B (zh) * 2012-03-15 2018-09-11 苏州泽璟生物制药有限公司 一种改善吸收性能的固体分散体及其制备
US9724354B2 (en) 2013-03-22 2017-08-08 Millennium Pharmaceuticals, Inc. Combination of catalytic mTORC1/2 inhibitors and selective inhibitors of Aurora A kinase
US10561627B2 (en) * 2014-12-31 2020-02-18 Eric Morrison Ibuprofen nanoparticle carriers encapsulated with hermetic surfactant films
SG10202103552XA (en) 2015-03-09 2021-05-28 Intekrin Therapeutics Inc Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy
AU2018249822A1 (en) 2017-04-03 2019-10-31 Coherus Biosciences Inc. PPArgamma agonist for treatment of progressive supranuclear palsy
US12053447B2 (en) 2019-06-25 2024-08-06 NuBioPharma, LLC Oral solution and powder to liquid compositions of balsalazide

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9401090D0 (en) 1994-01-21 1994-03-16 Glaxo Lab Sa Chemical compounds
KR0179401B1 (ko) * 1994-02-28 1999-03-20 송택선 신규한 5-피롤릴-2-피리딜메틸설피닐벤즈이미다졸 유도체
US6358932B1 (en) 1994-05-31 2002-03-19 Isis Pharmaceticals, Inc. Antisense oligonucleotide inhibition of raf gene expression
US6391636B1 (en) 1994-05-31 2002-05-21 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of raf gene expression
US6037136A (en) 1994-10-24 2000-03-14 Cold Spring Harbor Laboratory Interactions between RaF proto-oncogenes and CDC25 phosphatases, and uses related thereto
US5717100A (en) 1995-10-06 1998-02-10 Merck & Co., Inc. Substituted imidazoles having anti-cancer and cytokine inhibitory activity
IL127210A0 (en) 1996-05-23 1999-09-22 Applied Research Systems Compounds inhibiting the binding of raf-1 or 13-3-3 proteins to the beta-chain of il-2 pharmaceutical compositions containing them and their use
AR012634A1 (es) 1997-05-02 2000-11-08 Sugen Inc Compuesto basado en quinazolina, composicion famaceutica que lo comprende, metodo para sintetizarlo, su uso, metodos de modulacion de la funcion deserina/treonina proteinaquinasa con dicho compuesto y metodo in vitro para identificar compuestos que modulan dicha funcion
US6187799B1 (en) 1997-05-23 2001-02-13 Onyx Pharmaceuticals Inhibition of raf kinase activity using aryl ureas
GB9716557D0 (en) 1997-08-06 1997-10-08 Glaxo Group Ltd Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
US6022884A (en) 1997-11-07 2000-02-08 Amgen Inc. Substituted pyridine compounds and methods of use
US6204467B1 (en) 1998-03-24 2001-03-20 Ford Global Technologies, Inc. Method and apparatus for resistive welding
ME00275B (me) 1999-01-13 2011-02-10 Bayer Corp ω-KARBOKSIARIL SUPSTITUISANI DIFENIL KARBAMIDI KAO INHIBITORI RAF KINAZE
US6391683B1 (en) * 2000-06-21 2002-05-21 Siliconware Precision Industries Co., Ltd. Flip-chip semiconductor package structure and process for fabricating the same
WO2002018654A1 (en) 2000-08-30 2002-03-07 The Board Of Trustees Of The University Of Arkansas Induction of ldl receptor expression by extracellular-signal regulated kinase, erk-1/2
AU2001262945B2 (en) * 2000-09-20 2006-02-02 Skyepharma Canada Inc. Spray drying process and compositions of fenofibrate
US20040131670A1 (en) * 2001-04-17 2004-07-08 Ping Gao Pellicle-resistant gelatin capsule
US20030198666A1 (en) * 2002-01-07 2003-10-23 Richat Abbas Oral insulin therapy
GB0205693D0 (en) * 2002-03-09 2002-04-24 Astrazeneca Ab Chemical compounds
CA2480638C (en) * 2002-03-29 2013-02-12 Chiron Corporation Substituted benzazoles and use thereof as raf kinase inhibitors
US8299108B2 (en) 2002-03-29 2012-10-30 Novartis Ag Substituted benzazoles and methods of their use as inhibitors of raf kinase
US20050082192A1 (en) * 2002-06-17 2005-04-21 Eric Smarr End cap support for jumbo rolls of material
WO2005112932A2 (en) * 2004-05-07 2005-12-01 Exelixis, Inc. Raf modulators and methods of use
PE20070427A1 (es) * 2005-08-30 2007-04-21 Novartis Ag Compuestos derivados de benzimidazoles sustituidos como inhibidores de tirosina quinasas
US20100231394A1 (en) * 2009-03-11 2010-09-16 Bobby Eugene Finchum Carbon monoxide detection and dissipation apparatus

Also Published As

Publication number Publication date
AU2007275634B2 (en) 2011-01-20
HRP20100293T1 (hr) 2010-06-30
DE602007005139D1 (de) 2010-04-15
ES2340631T3 (es) 2010-06-07
RU2452469C2 (ru) 2012-06-10
CN101516335B (zh) 2014-01-08
EP2046292A2 (en) 2009-04-15
WO2008011154A3 (en) 2008-06-26
RU2012107218A (ru) 2013-09-10
PT2046292E (pt) 2010-04-26
KR20090033904A (ko) 2009-04-06
RU2009105819A (ru) 2010-08-27
WO2008011154A2 (en) 2008-01-24
DK2046292T3 (da) 2010-06-07
BRPI0715423A2 (pt) 2013-07-02
CN101516335A (zh) 2009-08-26
PL2046292T3 (pl) 2010-08-31
US20100040677A1 (en) 2010-02-18
EP2046292B1 (en) 2010-03-03
JP2009544617A (ja) 2009-12-17
ATE459338T1 (de) 2010-03-15
US8455662B2 (en) 2013-06-04
AU2007275634A1 (en) 2008-01-24
CY1110037T1 (el) 2015-01-14
MX2009000770A (es) 2009-01-28
CA2657346A1 (en) 2008-01-24

Similar Documents

Publication Publication Date Title
SI2046292T1 (sl) Formulacije za benzimidazolil piridil etre
WO2005112633A3 (en) Compounds and compositions for delivering active agents
MX2009008540A (es) Inhibidores de virus de hepatitis c macrociclicos sustituidos con pirimidina.
WO2007027941A3 (en) Compositions and methods for preparation of poorly water soluble drugs with increased stability
WO2007008752A3 (en) Sustained release pharmaceutical compositions for highly water soluble drugs
TW200716202A (en) Pediatric formulation of topiramate
WO2007087548A3 (en) Chemical compounds
EP1714961A4 (en) INDAZOL COMPOUND AND THEIR PHARMACEUTICAL USE
WO2008115516A8 (en) 4'-o-substituted isoindoline derivatives and compositions comprising and methods of using the same
WO2006035417A3 (en) Dihydropyrimidine microcapsule - formulations
WO2007090141A3 (en) Pyrrolo [2, 3, b] pyridine derivatives useful as raf kinase inhibitors
WO2007075972A3 (en) Chlorite formulations, and methods of preparation and use thereof
WO2007100382A3 (en) Orally administrable gallium compositions and method of use
WO2010015567A3 (en) Controlled release formulations using intelligent polymers
WO2008006795A3 (en) Indole compounds
WO2009016498A8 (en) Pyrimidine and pyridine derivatives and their pharmaceutical use and compositions
MX2008001560A (es) Nuevos compuestos analogos de la camptotecina, un procedimiento para su preparacion y composiciones farmaceuticas que los contienen.
GEP20125707B (en) Chromane derivatives as trpv3 modulators
WO2009026257A3 (en) Methods and compositions for controlling the bioavailability of poorly soluble drugs
WO2006034147A3 (en) Compositions and methods for the preparation and administration of poorly water soluble drugs
WO2008004100A9 (en) Therapeutic compounds
HK1120417A1 (en) Stable nanoparticle formulations
WO2008039894A3 (en) Atorvastatin pharmaceutical compositions
WO2007022532A3 (en) Cyclopropyl compounds and compositions for delivering active agents
MX2009001572A (es) Derivados de arilpiperazina y usos de los mismos.